Compare H.U. Group Holdings, Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -28.61% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate -28.61% of over the last 5 years
3
The company has declared positive results for the last 3 consecutive quarters
4
With ROCE of 3.12%, it has a very attractive valuation with a 1.32 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 192,255 Million (Small Cap)
27.00
NA
0.00%
0.11
5.03%
1.40
Revenue and Profits:
Net Sales:
60,633 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,188 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.81%
0%
25.81%
6 Months
36.27%
0%
36.27%
1 Year
39.25%
0%
39.25%
2 Years
21.74%
0%
21.74%
3 Years
28.13%
0%
28.13%
4 Years
19.75%
0%
19.75%
5 Years
29.71%
0%
29.71%
H.U. Group Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.09%
EBIT Growth (5y)
-28.61%
EBIT to Interest (avg)
38.50
Debt to EBITDA (avg)
0.97
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
1.16
Tax Ratio
21.87%
Dividend Payout Ratio
102.87%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
10.14%
ROE (avg)
10.97%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
1.36
EV to EBIT
42.30
EV to EBITDA
7.62
EV to Capital Employed
1.32
EV to Sales
0.82
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
3.12%
ROE (Latest)
5.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
60,633.00
62,337.00
-2.73%
Operating Profit (PBDIT) excl Other Income
5,795.00
7,321.00
-20.84%
Interest
167.00
176.00
-5.11%
Exceptional Items
-230.00
429.00
-153.61%
Consolidate Net Profit
1,188.00
5,374.00
-77.89%
Operating Profit Margin (Excl OI)
9.90%
29.70%
-1.98%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.73% vs -1.05% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -77.89% vs 291.41% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
247,362.00
243,025.00
1.78%
Operating Profit (PBDIT) excl Other Income
26,537.00
23,092.00
14.92%
Interest
686.00
591.00
16.07%
Exceptional Items
-73.00
-360.00
79.72%
Consolidate Net Profit
6,704.00
2,731.00
145.48%
Operating Profit Margin (Excl OI)
19.30%
9.70%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.78% vs 2.56% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 145.48% vs 136.16% in Mar 2025
About H.U. Group Holdings, Inc. 
H.U. Group Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






